Stemline Therapeutics Inc. (STML)

15.25
NASDAQ : Health Technology
Prev Close 14.43
Day Low/High 14.44 / 15.39
52 Wk Low/High 7.82 / 18.22
Avg Volume 467.40K
Exchange NASDAQ
Shares Outstanding 48.96M
Market Cap 706.44M
EPS -3.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Stemline Therapeutics Announces Pricing Of $76,250,000 Public Offering Of Common Stock

Stemline Therapeutics Announces Pricing Of $76,250,000 Public Offering Of Common Stock

NEW YORK, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc .

Stemline Therapeutics Announces Proposed Public Offering Of Common Stock

Stemline Therapeutics Announces Proposed Public Offering Of Common Stock

NEW YORK, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc.

Stemline Therapeutics Announces That CMS Grants New Technology Add-on Payment (NTAP) To ELZONRIS®

Stemline Therapeutics Announces That CMS Grants New Technology Add-on Payment (NTAP) To ELZONRIS®

NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc.

Stemline Therapeutics Reports Second Quarter 2019 Financial Results

Stemline Therapeutics Reports Second Quarter 2019 Financial Results

Net revenue for ELZONRIS® was $13.0 million for the second quarter Conference call and live webcast scheduled for today at 8:00 AM ET NEW YORK, Aug.

Stemline Therapeutics To Host Conference Call On Second Quarter 2019 Financial Results On August 2, 2019

Stemline Therapeutics To Host Conference Call On Second Quarter 2019 Financial Results On August 2, 2019

NEW YORK, July 29, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that the company will...

Stemline Therapeutics (STML) Shares Cross Below 200 DMA

Stemline Therapeutics (STML) Shares Cross Below 200 DMA

In trading on Monday, shares of Stemline Therapeutics Inc crossed below their 200 day moving average of $13.06, changing hands as low as $12.54 per share. Stemline Therapeutics Inc shares are currently trading off about 2.5% on the day.

Stemline Therapeutics Highlights Recent Clinical And Regulatory Developments And Details Upcoming Milestones Following Its Annual Shareholder Meeting

Stemline Therapeutics Highlights Recent Clinical And Regulatory Developments And Details Upcoming Milestones Following Its Annual Shareholder Meeting

NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, following its annual shareholder meeting,...

First Week Of August 16th Options Trading For Stemline Therapeutics (STML)

First Week Of August 16th Options Trading For Stemline Therapeutics (STML)

Investors in Stemline Therapeutics Inc saw new options become available this week, for the August 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the STML options chain for the new August 16th contracts and identified one put and one call contract of particular interest.

Stemline Therapeutics (STML) Shares Cross Above 200 DMA

Stemline Therapeutics (STML) Shares Cross Above 200 DMA

In trading on Wednesday, shares of Stemline Therapeutics Inc crossed above their 200 day moving average of $13.65, changing hands as high as $13.97 per share. Stemline Therapeutics Inc shares are currently trading up about 3.9% on the day.

First Week Of STML May 17th Options Trading

First Week Of STML May 17th Options Trading

Investors in Stemline Therapeutics Inc saw new options become available this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the STML options chain for the new May 17th contracts and identified one put and one call contract of particular interest.

Relative Strength Alert For Stemline Therapeutics

Relative Strength Alert For Stemline Therapeutics

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Oversold Conditions For Stemline Therapeutics (STML)

Oversold Conditions For Stemline Therapeutics (STML)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Newman Ferrara LLP Announces Corporate Governance Investigation Of Stemline Therapeutics Inc. - STML

Newman Ferrara LLP Announces Corporate Governance Investigation Of Stemline Therapeutics Inc. - STML

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Stemline Therapeutics Inc.

STML Makes Bullish Cross Above Critical Moving Average

STML Makes Bullish Cross Above Critical Moving Average

In trading on Tuesday, shares of Stemline Therapeutics Inc crossed above their 200 day moving average of $16.02, changing hands as high as $16.10 per share. Stemline Therapeutics Inc shares are currently trading up about 5.6% on the day.

Stemline Therapeutics Becomes Oversold (STML)

Stemline Therapeutics Becomes Oversold (STML)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Stemline Therapeutics Is Now Oversold (STML)

Stemline Therapeutics Is Now Oversold (STML)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

First Week of STML May 18th Options Trading

First Week of STML May 18th Options Trading

Investors in Stemline Therapeutics Inc saw new options begin trading this week, for the May 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the STML options chain for the new May 18th contracts and identified one put and one call contract of particular interest.

Commit To Buy Stemline Therapeutics At $10, Earn 16.4% Annualized Using Options

Commit To Buy Stemline Therapeutics At $10, Earn 16.4% Annualized Using Options

Investors considering a purchase of Stemline Therapeutics Inc shares, but tentative about paying the going market price of $13.57/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the June put at the $10 strike, which has a bid at the time of this writing of 70 cents.

Newman Ferrara LLP Announces Corporate Governance Investigation Of Stemline Therapeutics Inc. - STML

Newman Ferrara LLP Announces Corporate Governance Investigation Of Stemline Therapeutics Inc. - STML

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Stemline Therapeutics Inc.

TheStreet Quant Rating: D (Sell)